The Chemopreventive Agent Development Research Group promotes and supports research on early chemopreventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to identify and develop prevention agents with the potential to block, reverse, or delay the early stages of cancer. The overarching goal is to determine positive and negative predictive values of preclinical models for clinical development.
PREVENT Project Results Presented at AACR
NCI participated in the American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2018 at McCormick Place North/South in Chicago, IL, including the presentation of research results from nine PREVENT-supported projects.
PREVENT Cancer Preclinical Drug Development Program (PREVENT)
Research pipeline for new prevention interventions and biomarkers headed toward clinical trials.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Systematic early clinical development of promising preventive agents through five major medical research centers.